{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:39:44Z","timestamp":1774316384569,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T00:00:00Z","timestamp":1545436800000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health, USA","doi-asserted-by":"crossref","award":["AI104636"],"award-info":[{"award-number":["AI104636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Unither Virology"},{"name":"LLC"},{"name":"Commonwealth of Pennsylvania"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.antiviral.2017.12.008","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T12:56:15Z","timestamp":1513342575000},"page":"112-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Enhancing the antiviral potency of ER \u03b1-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo"],"prefix":"10.1016","volume":"150","author":[{"given":"Julia","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuexiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Soloveva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huagang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5058-5076","authenticated-orcid":false,"given":"Helen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Solon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Comunale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Bavari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4665-8348","authenticated-orcid":false,"given":"Yanming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-494X","authenticated-orcid":false,"given":"Jinhong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.12.008_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2016.11.018","article-title":"Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay","volume":"138","author":"Adcock","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1042\/BST20160182","article-title":"Iminosugar antivirals: the therapeutic sweet spot","volume":"45","author":"Alonzi","year":"2017","journal-title":"Biochem. Soc. Trans."},{"issue":"7","key":"10.1016\/j.antiviral.2017.12.008_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3851\/IMP3180","article-title":"In vitro susceptibility of geographically and temporally distinct zika viruses to favipiravir and ribavirin","volume":"22","author":"Baz","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2017.12.008_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1126\/science.aaa3778","article-title":"Infectious disease. Combating emerging viral threats","volume":"348","author":"Bekerman","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.12.008_bib5","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1073\/pnas.1704011114","article-title":"Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies","volume":"114","author":"Best","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"33","key":"10.1016\/j.antiviral.2017.12.008_bib6","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1073\/pnas.1704011114","article-title":"Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies","volume":"114","author":"Best","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"8","key":"10.1016\/j.antiviral.2017.12.008_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2017.12.008_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1099\/vir.0.18860-0","article-title":"A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication","volume":"84","author":"Bredenbeek","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib10","doi-asserted-by":"crossref","first-page":"E4630","DOI":"10.1073\/pnas.1604463113","article-title":"Structures of mammalian ER alpha-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals","volume":"113","author":"Caputo","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.antiviral.2017.12.008_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.antiviral.2013.06.011","article-title":"Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions","volume":"99","author":"Chang","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP2907","article-title":"Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections","volume":"20","author":"Chang","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2017.12.008_bib13","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1038\/emi.2013.77","article-title":"Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents","volume":"2","author":"Chang","year":"2013","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2017.12.008_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2010.11.002","article-title":"Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo","volume":"89","author":"Chang","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.antiviral.2011.08.003","article-title":"Competitive inhibitor of cellular alpha-glucosidases protects mice from lethal dengue virus infection","volume":"92","author":"Chang","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1128\/AAC.01457-08","article-title":"Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses","volume":"53","author":"Chang","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.12.008_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.antiviral.2013.03.023","article-title":"Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses","volume":"98","author":"Chang","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.chom.2016.04.013","article-title":"Structures of the zika virus envelope protein and its complex with a flavivirus broadly protective antibody","volume":"19","author":"Dai","year":"2016","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.antiviral.2017.12.008_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2017.12.008_bib20","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bmcl.2013.01.108","article-title":"N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections","volume":"23","author":"Du","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2017.12.008_bib21","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1016\/j.bmcl.2013.04.052","article-title":"Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus","volume":"23","author":"Du","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2017.12.008_bib22","first-page":"860","article-title":"Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection","volume":"10","author":"Durantel","year":"2009","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2017.12.008_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrd708","article-title":"Targeting glycosylation as a therapeutic approach","volume":"1","author":"Dwek","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2017.12.008_bib24","first-page":"139","article-title":"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells\/mm3","volume":"7","author":"Fischl","year":"1994","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2017.12.008_bib25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib27","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0002-9440(10)63591-2","article-title":"Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection","volume":"163","author":"Geisbert","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib28","doi-asserted-by":"crossref","first-page":"e2614","DOI":"10.1371\/journal.pntd.0002614","article-title":"Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a Guinea pig model of Argentine hemorrhagic fever","volume":"7","author":"Gowen","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2017.12.008_bib29","article-title":"RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response","volume":"7","author":"Guo","year":"2012","journal-title":"PLos One"},{"issue":"23","key":"10.1016\/j.antiviral.2017.12.008_bib30","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1128\/JVI.01253-16","article-title":"A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein","volume":"90","author":"Guo","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2014.04.010","article-title":"An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses","volume":"107","author":"Guo","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib32","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.84.7.2019","article-title":"Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it","volume":"84","author":"Hahn","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.antiviral.2017.12.008_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.12.008_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2017.07.010","article-title":"Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals","volume":"145","author":"Lanko","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00862-13","article-title":"Comprehensive functional analysis of N-linked glycans on Ebola virus GP1","volume":"5","author":"Lennemann","year":"2014","journal-title":"MBio"},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2017.12.008_bib36","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1093\/infdis\/jiv201","article-title":"The role of conserved N-Linked glycans on Ebola virus glycoprotein 2","volume":"212","author":"Lennemann","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.12.008_bib37","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(14)70730-3","article-title":"Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"14","author":"Low","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.12.008_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acsmedchemlett.6b00332","article-title":"Ester prodrugs of IHVR-19029 with enhanced oral exposure and prevention of gastrointestinal glucosidase interaction","volume":"8","author":"Ma","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2017.12.008_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/viro.1996.0406","article-title":"Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence","volume":"222","author":"Muylaert","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.12.008_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2017.12.008_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib42","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2017.12.008_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.antiviral.2013.01.004","article-title":"An iminosugar with potent inhibition of dengue virus infection in vivo","volume":"98","author":"Perry","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib44","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1128\/JVI.00028-15","article-title":"Dengue virus evolution under a host-targeted antiviral","volume":"89","author":"Plummer","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib45","first-page":"9","article-title":"Analysis of combinations of antiviral drugs and design of effective multidrug therapies","volume":"1","author":"Prichard","year":"1996","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2017.12.008_bib46","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1128\/AAC.01319-10","article-title":"Inhibitors of endoplasmic reticulum {alpha}-Glucosidases potently suppress hepatitis C virus virion assembly and release","volume":"55","author":"Qu","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.12.008_bib47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.4023707","article-title":"Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution","volume":"229","author":"Rice","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.12.008_bib48","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa1302846","article-title":"Glycosylation, hypogammaglobulinemia, and resistance to viral infections","volume":"370","author":"Sadat","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.12.008_bib49","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1086\/511310","article-title":"A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs","volume":"195","author":"Schul","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.12.008_bib50","article-title":"Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.antiviral.2017.12.008_bib51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121662","article-title":"In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4","volume":"10","author":"Stavale","year":"2015","journal-title":"PLos One"},{"key":"10.1016\/j.antiviral.2017.12.008_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib54","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2017.12.008_bib55","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0006-291X(87)91096-5","article-title":"Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing","volume":"148","author":"Sunkara","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2017.12.008_bib56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/1040841X.2016.1242868","article-title":"Iminosugars: promising therapeutics for influenza infection","volume":"43","author":"Tyrrell","year":"2017","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/315215","article-title":"Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity","volume":"181","author":"Vaughn","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.12.008_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/v8030071","article-title":"The iminosugar UV-4 is a broad inhibitor of influenza A and B Viruses ex vivo and in mice","volume":"8","author":"Warfield","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2017.12.008_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2016.03.001","article-title":"Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4","volume":"129","author":"Warfield","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.antiviral.2016.11.019","article-title":"Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo","volume":"138","author":"Warfield","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib61","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.12.008_bib62","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.12.008_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.12.008","article-title":"Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: the search for a window for potential therapeutic efficacy","volume":"127","author":"Watanabe","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2012.07.008","article-title":"Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial","volume":"96","author":"Watanabe","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","volume":"126","author":"Westover","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.008_bib66","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1128\/JVI.79.14.8698-8706.2005","article-title":"Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo","volume":"79","author":"Whitby","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib67","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.12.008_bib68","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1128\/JVI.76.8.3596-3604.2002","article-title":"Antiviral effects of an iminosugar derivative on flavivirus infections","volume":"76","author":"Wu","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib69","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1128\/JVI.02424-12","article-title":"Membrane topology and function of dengue virus NS2A protein","volume":"87","author":"Xie","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.12.008_bib70","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41598-017-06612-2","article-title":"Evaluation of Sofosbuvir (beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine) as an inhibitor of Dengue virus replication","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2017.12.008_bib71","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1021\/jm300171v","article-title":"Design, synthesis, and biological evaluation of N-Alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection","volume":"55","author":"Yu","year":"2012","journal-title":"J. Med. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:26:32Z","timestamp":1759062392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217306514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":71,"alternative-id":["S0166354217306514"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing the antiviral potency of ER \u03b1-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}